Swedish Medtech start-up Capitainer raises SEK15 million to commercialise Capitainer qDBS dried blood spot sampling system
Stockholm, March 11, 2020: The Swedish Medtech start-up, Capitainer, today announced that it has closed a share issue of SEK15 million to commercialise its new dried blood spot sampling solution, Capitainer qDBS. Lead investors are Nordic Consumer Health and the US-based Wolf Family Trust, joined by a consortium of Nordic angel investors and Capitainer management.
The Capitainer qDBS solution is designed to enable convenient and quantitative blood sampling at the fingertip. The patented solution ensures an exact sample volume of 10µl blood to be collected. Patients simply place a blood drop on the qDBS card which automatically fills a microchannel with the required amount and discards any excess. The potential for human error is thus completely eliminated. Subsequently, the blood volume contained in the microchannel automatically transfers to a pre-punched DBS paper, forming an accurate and high-quality dried blood spot sample, preserved for quantitative analysis. The filled card can then be safely transported to the laboratory for analysis without the need for refrigeration or specialised packaging. Capitainer blood sampling therefore delivers cost savings, improved healthcare efficiency and patient experience, as well as reducing environmental impact.
“The dried blood spot collection card market size is currently expected to reach USD 337.3 million by 2026, expanding at a CAGR of 3.5%. However, with our next generation device, Capitainer qDBS with quantitative and easy to use sampling, we will not only expand the existing market, but also be able to enter the clinical home sampling market which we believe is a billion dollar USD market. We aim at making Capitainer products the new gold standard for home sampling of blood. As a founding investor, we are delighted to lead this round and look forward to a successful commercialisation,” says Mats Bergryd, CEO of Nordic Consumer Health.
“From wellness screening to serological diagnostics of infectious- and autoimmune diseases, the potential for Capitainer qDBS to further increase its already positive impact on healthcare provision and outcomes is enormous and we are delighted to invest in this round,” adds Bob Wolf, Founder and President of Specialty Diagnostix.
Christopher Aulin, CEO of Capitainer comments: “Over the last 12 months, we have seen a growing interest in Capitainer qDBS for both existing and new applications such as therapeutic drug monitoring, genomics and screening applications. With the fast growing demands for home sampling, we strongly believe that capillary blood will increasingly be seen as a viable and preferable alternative to venous blood. I would like to thank our investors, both new and existing, for their confidence and this funding will now enable us to accelerate our commercialisation activities for Capitainer qDBS.”
For more information, visit www.capitainer.se
Contact
Christopher Aulin, CEO t: +46 708 977 577
e: aulin@capitainer.se
Notes
Capitainer AB is a Swedish Medtech company founded in 2013 by Professor Olof Beck from the Department of Clinical Pharmacology at the Karolinska Institute and Professors Göran Stemme, Asso. Prof. Niclas Roxhed and PhD Gabriel Lenk from the division of Micro- and Nanosystems at the Royal Institute of Technology (KTH), Sweden and Peter Bräutigam, a business consultant.
Capitainer is a supplier of intelligent solutions for Dried Blood and Plasma Spot sampling serving several market segments, including but not limited, to Therapeutic Drug Monitoring, Drug Development and Drugs of Abuse and Alcohol testing. By using a combination of paper- and polymer microfluidics the precision and accuracy of metering of capillary blood is on par with that of a standard displacement pipette. Thus, the technology enables more convenient solutions for healthcare sampling and patients’ home sampling ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma.
Read more news
Capitainer’s qDBS dried blood spot system for home self-sampling proves 97% effective for clinical mass-testing of Covid-19 vaccine efficacy
Capitainer’s qDBS dried blood spot system for home self-sampling proves 97% effective for clinical mass-testing of Covid-19 vaccine efficacy
Capitainer attracts former Karolinska University Hospital Laboratory Unit Manager Mikael Ström as Business Development Manager
Capitainer attracts former Karolinska University Hospital Laboratory Unit Manager Mikael Ström as Business Development Manager
Sweden’s Västerbotten Region first to introduce home sampling for COVID-19 antibodies together with Capitainer
Sweden’s Västerbotten Region first to introduce home sampling for COVID-19 antibodies together with Capitainer
New study shows that the new Capitainer PEth system tailored for analysis of PEth enables accurate and court-admissible monitoring of alcohol abuse
New study shows that the new Capitainer PEth system tailored for analysis of PEth enables accurate and court-admissible monitoring of alcohol abuse
Capitainer’s qDBS dried blood spot system for home sample collection employed in a nation-wide COVID-19 study in the US
Capitainer’s qDBS dried blood spot system for home sample collection employed in a nation-wide COVID-19 study in the US
Capitainer raises further SEK31 million to meet anticipated demand for qDBS dried blood spot sampling system as COVID-19 vaccine programs are rolled out
Stockholm, January 19, 2021: Swedish medtech start-up Capitainer today announced that it has closed a share issue of SEK31 million to roll out its new qDBS dried blood spot testing system.
Capitainer awarded ISO 13485:2016 as interest grows in qDBS testing for COVID-19 and other challenging applications
Stockholm, November 11, 2020: Capitainer AB, a medtech company committed to making Dried Blood Spot testing universal, is pleased to announce that the company has received the International Organization for Standards (ISO) 13485:2016 certification for...
Capitainer inks European and Asia Pacific distribution deal with Speciality Diagnostix for qDBS dried blood spot sampling system
Stockholm, September, 2020: Swedish med-tech start-up Capitainer today announced it has signed a distribution deal with Speciality Diagnostix for Europe and Australia/New Zealand. The deal comes amid increasing interest driven by COVID-19 in Capitainer’s...
Swedish medtech start-up Capitainer hires VWR veteran Tom Sölch as COO amid mounting interest in novel qDBS dried blood spot sampling system for COVID-19 testing and other key applications
Stockholm, September 1, 2020: Swedish medtech start-up Capitainer hires VWR veteran Tom Sölch as COO amid mounting interest in novel qDBS dried blood spot sampling system for COVID-19 testing and other key applications Swedish medtech start-up Capitainer...
TV4 news in Stockholm: 10% of Stockholm residents infected with Covid-19 based on homesampling study performed by KTH Royal Institute of Technology.
Stockholm May 4, 2020:First result from the research study with one thousand randomely citizens of Stockholm, in Sweden, doing home sampling using Capitainer for Covid-19 immunity The Capitainer qDBS solution is designed to enable convenient and...
A research study where one thousand randomely citizens of Stockholm, in Sweden, are doing home sampling using Capitainer for Covid-19 immunity – links to TV-spots and news
Stockholm April 7, 2020: A research study has started with one thousand randomely citizens of Stockholm, in Sweden, doing home sampling using Capitainer for Covid-19 immunity The Capitainer qDBS solution is designed to enable convenient and quantitative...
Capitainer AB, Linköping University and Karolinska University Hospital have been awarded 3M SEK
Capitainer AB, Linköping University and Karolinska University Hospital have been awarded 3M SEK in a joint call; “Samverkansprojekt för bättre hälsa”, by Vinnova (www.vinnova.se) , Swelife (www.swelife.se) and Medtech4Healths (www.medtech4health.se)....
Patent on the novel Capitainer B product approved in the US
Capitainer has had the patent on the novel Capitainer-B product approved in the US and it will shortly be granted. This is a very important step for Capitainer since we see a strong interest from the US market in our product and technology. The novel...
Capitainer-B – “effectively assist in eliminating the hematocrit-based area bias”
"The new Capitainer B device "effectively assist in eliminating the hematocrit-based area bias", compared to traditional DBS, independently of the applied blood volume. Take a look at the excellent supporting study by Velghe and Stove. Read more...
Meet us at IATDMCT Congress in Brisbane 16-19/9
Capitainer participates in (IATDMCT) Congress 2018, 16–19 September 2018 in Brisbane, Australia The 16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2018) will be held from Sunday 16th to Wednesday 19th...
Meet us at AACC Annual Scientific Meeting
Capitainer participates in AACC Annual Scientific Meeting July29-August 2, 2018 The 70th AACC Annual Scientific Meeting & Clinical Lab Expo is the largest global scientific conference and tradeshow in the field of laboratory medicine. This is part of...
Capitainer B is CE-marked and is being made available for the European market!
We have, as per April 30th, had our Novel micro sampling product, the Capitainer B, CE marked and registered with the Swedish Medical Product Agency (Läkemedelsverket). The Capitainer B is registered as an IVD product according to the 98/97EC In vitro...
Capitainer will attend Vårmöte i klinisk kemi 24-26 april 2018 in Uppsala
Capitainer will participate in Spring Meeting in Clinical Chemistry, 24-26 April 2018 in Uppsala. Welcome to our booth and the seminar entitled "Measuring Peth in capillary blood as a dried blood stain" with Olof Beck, PhD, CSO and co-founder. Time: Wedensdagy 10:...
Meet us at Medtec Europe 17-19 april Messe, Stuttgart Germany
Capitainer participates in Medtec Europe 17-19 april 2018, in Stuttgart Germany. Meet us in stand: 10B64 Medtec Europe is the preeminent medical technology platform showcasing the key trends and insights across the entire supply chain of the medical technology...
Capitainer participates and sponsors CPSA Europe 2018
Capitainer participates in, and sponsors, the inaugural European symposium on Clinical & Pharmaceutical Solutions through Analysis -CPSA Europe 2018, in Cambridge, UK. This is part of our strategy to promote the Capitainer concept to the most...
Capitainer invited speaker at PRINSE’18
Capitainer was invited speaker in the diagnostics session at PRINSE’18 (the 5th Printed Intelligense Industry Seminar) this year focusing on ”Manufacturing Solutions for Customer Needs and Vision to the Future”, Jan 31- Feb 1, 2018, in Oulu, Finland. The...
Ernst Westman new Chairman of the Board
The board of directors has elected Mr. Ernst Westman as new Chairman of the Board of Capitainer AB. Mr. Westman has been President and CEO of the listed blood diagnostics Boule Diagnostics AB (publ) between 1994 to 2017 and now takes over the leadership in...
Ta blodprovet själv, KTH magazine
Hjärtpatienten Sigvard sitter hemma i köket och förbereder ett blodprov på sig själv. Efter hjärtattacken för ett halvår sedan behandlas han med den blodförtunnande medicinen Waran för att minska risken för återfall. Ett problem med Waran är att doseringen är väldigt...
Capitainer receives 10 million SEK in initial funding round
In an initial funding round, Nordic Consumer Health AB invests 10 million SEK in Capitainer AB. The funds will be used to capitalize the company during the upcoming year and to perform activities in product development, clinical trials and home sampling studies,...
Capitainer finalist at Stockholm Innovation Award
Stockholm, the capital of Sweden, has selected Capitainer as finalist for the Stockholm Innovation Award, an award for Stockholm's most promising business ideas. Read more news Get In Touch We are currently seeking funding to reach set-up milestones. We welcome...
Capitainer Featured on KTH Home Page
Capitainer technology is highlighted as a news article on KTH’s first page. Read more news Get In Touch We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam for further...
Capitainer Selected Best Start-Up
Capitainer was selected best Start-Up at the Nordic Pitch Night event Aug 25 in Silicon Valley, USA Read more news Get In Touch We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam for...
Nordic Life Science Days, Sept. 14-15 in Stockholm
Capitainer has been selected to exhibiting at the Nordic Life Science days Sept. 14-15 in Stockholm. Read more news Get In Touch We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam...
AACC Annual Scientific Meeting & Clinical Lab Expo
Capitainer is presenting their technology at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo Aug 1-4, in Philadelphia, USA. Read more news Get In Touch We are currently seeking funding to reach set-up milestones. We welcome investors interested...
Brighter Startup Program
Capitainer is attending the Brighter Startup Program, a one week program for Swedish entrepreneurs located in Silicon Valley’s unique and leading innovation and entrepreneurship ecosystem. Read more news Get In Touch We are currently seeking funding to reach...
